Kedrion Biopharma

Kedrion Biopharma is a leading biopharmaceutical company specializing in the collection and fractionation of blood plasma to develop and distribute plasma-derived therapies globally for the treatment and prevention of rare and serious diseases. In 2022, Kedrion made a significant move by partnering with Bio Products Laboratory (BPL), a company with over 60 years of experience in supplying high-quality plasma-derived medicines for rare diseases based in the United Kingdom. Kedrion has a strong international presence, distributing its products across over 100 countries, with manufacturing facilities in Italy, Hungary, the UK, and North America, as well as plasma collection centers in the US and the Czech Republic. The company's recent Private Equity Round investment at 01 September 2022 from Permira signifies a strong financial backing for its expansion and innovation. Kedrion's dedication to building a diverse and professional workforce demonstrates a commitment to fostering talent and progression within the company, offering opportunities for both external candidates and internal employees to thrive. The company's mission of connecting donors to patients and turning challenges into hope encapsulates its impactful work in the healthcare industry. With its position as the world's 5th top player in the field of plasma-derived products, Kedrion Biopharma represents a significant player in the global healthcare landscape.